Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PYROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus PYROLITE.
MPI INDIUM DTPA IN 111 vs PYROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Pyrolite is not a recognized pharmaceutical drug. No mechanism of action data available.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
1000 mg orally every 8 hours for 7 days.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Terminal half-life: 4.5 hours (range 3.8–5.2). Clinical context: Eliminated rapidly; no accumulation with q6h dosing; dose adjustment needed in CrCl <30 mL/min.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal: 70% unchanged; Fecal: 20% as metabolites; Biliary: 10% as conjugates.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical